However, Magrin et al. [31] found in their study on 100 patients with HCV-RNA positive chronic liver disease that, in absence of cirrhosis, low pre-treatment serum HCV-RNA level is the most important predictor of response to IFN therapy. This evidence concerns the gene IFNA1 and Cirrhosis.